Abstract
Background -Polymerase chain reaction (PCR) amplification of Mycobacterium tuberculosis DNA offers the potential of a sensitive and specific diagnostic test for tuberculosis. To evaluate this technique from the clinician's perspective, samples were collected from patients with chronic respiratory disease and the sensitivity and specificity of a newly introduced commercially available PCR kit (Amplicor) was compared with that of an established method to detect the target sequence IS6110. Methods -Sputum or bronchial washings from patients with active tuberculosis, previously treated tuberculosis or other selected respiratory illnesses were analysed by both techniques and their sensitivity and specificity determined. Results -Amplicor was more specific than IS6110 in the diagnosis of active infection (98% versus 79%). Both Amplification of DNA sequences specific to Mycobacterium tuberculosis by polymerase chain reaction (PCR) offers the potential of a rapid and specific diagnostic test. 1 The most commonly used sequence is IS6110.2 However, our group3 has found evidence of IS6110 DNA in respiratory samples from patients living in an area with a high prevalence of tuberculosis who do not themselves have active tuberculosis. There is also doubt about the interlaboratory reproducibility of IS6110 PCR methodology.4 A further problem is that most studies are laboratory based and samples are included irrespective of the clinical status of the patient. The Amplicor PCR system (Roche Molecular Systems, Branchburg, New Jersey, USA) for the detection of M tuberculosis DNA has recently been introduced. This uses an alternative target sequence of DNA which encodes the 16S ribosomal RNA (rRNA) gene and incorporates techniques to prevent contamination by previously amplified samples. The target sequence of DNA is present in one copy of the chromosome and has been used by others. 5 The method avoids the need for a reverse transcription step required if the equivalent sequence of the rRNA is used. 6 We have undertaken a study to determine whether the Amplicor system is better able to discriminate between patients with active tuberculosis requiring treatment and those with other chronic respiratory conditions including past tuberculosis than PCR for IS6 110. To this end samples were examined which had been collected from specifically selected groups of patients with chronic respiratory disease who lived in an area with a high prevalence of tuberculosis.
Methods
Sputum or bronchial washings were collected from selected inpatients and outpatients attending St Mary's Respiratory Medicine Service. Over a three month period, a sputum specimen was obtained from all patients diagnosed as having pulmonary tuberculosis before or within 48 hours of commencing treatment. Similarly, sputum was obtained from patients previously treated for tuberculosis attending the outpatients who had been treated with a conventional rifampicin based regimen and a few currently on treatment. Patients with other selected chronic respiratory diseases including cancer, chronic obstructive airways disease, bronchiectasis, and sarcoidosis (table) were recruited and those with a productive cough provided a sputum sample. Patients in these groups without a productive cough who were undergoing diagnostic fibreoptic bronchoscopy were recruited and 10 ml of bronchial trap fluid was collected. All The sputum samples were decontaminated with NaOH sodium citrate N-acetyl-L-cysteine and concentrated after decontamination.7
To 100 tld of decontaminated sputum or bronchial washings was added 500 isl of sputum wash solution. The samples were vortexed and centrifuged at 12 5OOg for 10 minutes; 100 gl of sputum lysis reagent was added to the pellet and vortexed. Positive and negative controls were prepared as follows. Briefly, to 100 jl of positive and negative controls (provided with the Amplicor kit) was added 400 1l of the sputum lysis reagent. 100 g1 of controls and processed specimens were incubated at 600C in dry heat block for 45 minutes. The tubes were pulse centrifuged for five seconds and 100,l of sputum neutralisation reagent was added. All the reagents were provided with the Amplicor kit.
A 584 base pair sequence using genus specific primers located in a highly conserved region of 16S ribosomal RNA (rRNA) gene of mycobacteria was amplified. The study included three patients on treatment for pulmonary tuberculosis. M tuberculosis DNA was found by Amplicor in none of the samples from these patients on treatment, but from two patients using IS6110 PCR. When diagnoses other than active tuberculosis were considered, the Amplicor PCR was more specific in that it identified M tuberculosis DNA in a sample from only one patient (who had lung cancer) out of the 63 who had no evidence of active tuberculosis and who were not receiving treatment for tuberculosis. By contrast, PCR for IS6110 DNA was less specific and gave positive results in samples from 14 patients who did not have active tuberculosis; these included two patients with past tuberculosis, four with lung cancer, two with chronic obstructive airways disease, five with bronchiectasis, and one with vasculitis. When the patients on therapy were excluded the sensitivity of the Amplicor test was 92% and the specificity 98%, whereas IS6110 detection had 
